Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

NCT07174453 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

192

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor Malignancies

Interventions

DRUG: Nivolumab
DRUG: Pembrolizumab

Sponsor

University of Kansas Medical Center